,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['bcsm', 'breast', 'destiny-breast04']
 destiny-breast04 results are practice changing with #tdxd showing benefit in low her2 expressing tumors irrespective of er status. potential improvement in pfs and os for ~50% of pretreated breast patients #bcsm #asco22 
#BreastCancer Oncologist | #Immunotherapy @OSUCCC_James @PIIO_OSU | Assoc Ed @jitcancer | #BoyMom | #WomenInMedicine | #HoyaSaxa | #NIH alumnus | Tweets-My Own